HIGHLIGHT

Perinatal programming of appetite control by leptin?

Jörg Dötsch, Wolfgang Rascher and Udo Meißner

Klinik für Kinder und Jugendliche, Universität Erlangen-Nürnberg, Germany

(Correspondence should be addressed to J Dötsch, Department of Pediatrics, Friedrich-Alexander-University Erlangen, Loschgestrasse 15, 91054 Erlangen, Germany; Email: joerg.doetsch@kindermed.uni-erlangen.de)

The concept of fetal and perinatal programming of neuroendocrine functions has attracted growing interest within the last 15 years. Barker (1) first demonstrated the relationship between low birth weight and diseases of later adulthood such as coronary heart disease and the metabolic syndrome. Meanwhile, there is convincing evidence that intrauterine factors such as placental insufficiency lead to a change of the metabolic and endocrine milieu in the feto-placental interface. These changes influence birth weight and also lead to persistent remodelling of endocrine functions (2, 3). Perinatal programming, therefore, implies persistent epigenetic changes of primarily genetic neuroendocrine functions. Finding the underlying mechanisms for the perinatal programming of a disease such as the metabolic syndrome – a disease associated with tremendous socioeconomic consequences – would be the first step towards initiating innovative concepts for preventive measures.

In a different but related field dealing with the early determination of neuroendocrine function needed later in life, namely the specification of sexually dimorphic patterns in the mammalian forebrain (4), recent advances have been made: specifically the surge of sex steroid secretion in early neonatal life has been linked to neuroanatomical and functional changes in the forebrain (5–7).

With regard to the regulation of appetite and energy consumption, the discovery of the predominantly adipocyte-derived hormone leptin in the mid-1990s has led to a new understanding (8). Leptin, at least in rodents, leads to a decreased food intake by stimulating neurons in the arcuate nucleus of the hypothalamus, one of the regions that contain the anorectic peptide 

\[
\text{leptin} \rightarrow \text{arcuate nucleus of the hypothalamus} \rightarrow \text{decreased food intake}
\]

This is a well-established paradigm that has been extensively explored in animal models. However, the question of whether a similar mechanism operates in humans is still open. Recent studies in rodents have shown that leptin also has trophic effects on neuronal development and growth. Specifically, leptin appears to be shared by the different species (10). Trophic effects of leptin on the very neurons that transmit its message in the hypothalamus, therefore, could account in part for the – to date missing – links between alterations in energy metabolism and its regulating hormones in fetal and early postnatal life, and the programming of appetite regulation later in life. To prove this hypothesis, several preconditions need to be met:

1. A fetal or early neonatal leptin surge leading to the induction of neuron proliferation. This appears to be the case (5).
2. The effect has to be specific, i.e. leptin must predominantly lead to the formation of hypothalamic neurons that convey the leptin signal and not proliferation in general.
3. In leptin-deficient ob-mice the phenomenon should be missing but should be restored by leptin application to these animals in the critical phase for neuron formation and growth.
4. The trophic effect on neuron formation is only present in the susceptible phase of neuron development.
5. The effect triggered in the developmental phase must persist until adulthood.

In their excellent articles (9, 11), Bouret and co-workers address the question whether the neonatal leptin surge in mice is able to induce the formation of nerve fibres that contain α-MSH, NPY and AgRP. By implanting crystals of the tracer 1,1'-dioctadecyl-3,3',3'-Y-tramethyldi-carbocyanine perchlorate (Dil) into the arcuate nucleus of mice the authors could monitor anterograde neuron formation into the surrounding hypothalamic nuclei. They found a ten times lower number of labelled neurons in the arcuate and the paraventricular nucleus when comparing leptin-deficient ob-mice to wild-type littersmates. This profound reduction was still demonstrated in the adult animals at day 60 of life. The decrease in neuron formation was not found in other hypothalamic nuclei or nervous projections to the limbic system, demonstrating the selectivity of this effect. The fibres that were reduced could indeed be identified to be those containing α-MSH and AgRP using immunostaining techniques. This demonstrates that fibres known to transmit the leptin message were involved.
Leptin treatment of neonatal ob-mice on days 4–12 of life reversed the reduction in nerve fibres underlining the specific role of leptin in neuron formation to a level seen in wild-type littermates (9). Most importantly, treatment of leptin-deficient adult mice with leptin for 20 days did not result in the formation of anorexigenic and orexigenic nerve fibres. This confirms that there is a critical period for the formation of leptin-dependent neurons in mice.

Interestingly, in the same issue of Science in which the article by Bouret and co-workers (11) appeared, Pinto and colleagues (12) present data on the role of leptin on synapse formation in the arcuate nucleus of the hypothalamus. In adult ob-mice leptin leads to the formation of new synapses even if the animals had been leptin deficient before. This suggests that leptin still has effects on hypothalamic neuronal plasticity in the adult animal, despite the reduction in anorexigenic and orexigenic nerve fibres.

In summary, the work by Bouret and co-workers (11) suggests a potential mechanism by which changes in leptin concentration during fetal and neonatal life may alter hypothalamic structures that influence food intake and energy metabolism until adult life. This might be the first step in elucidating mechanisms being important to explain the concept of fetal programming of adult disease.

References
1 Barker DJP. In utero programming of chronic disease. Clinical Science 1998 95 115–128.

Received 17 May 2004
Accepted 18 May 2004